ANAPTYSBIO INC. - COMMON STOCK

AnaptysBio Announces Portfolio Update Across Best-in-Class Immune Cell Modulating Antibodies

05 Jan 2023 16:05:00 By Nasdaq GlobeNewswire

AnaptysBio- and GSK-partnered immuno-oncology agent JEMPERLI (dostarlimab-gxly) meets primary endpoint in Phase 3 RUBY trial in primary advanced or recurrent endometrial cancer

02 Dec 2022 09:00:00 By Nasdaq GlobeNewswire

AnaptysBio to Participate at the Piper Sandler 34th Annual Healthcare Conference

21 Nov 2022 13:56:39 By Nasdaq GlobeNewswire

AnaptysBio to Participate in Upcoming November Investor Conferences

09 Nov 2022 14:10:17 By Nasdaq GlobeNewswire

AnaptysBio Announces Third Quarter 2022 Financial Results and Provides Pipeline Update

08 Nov 2022 16:05:01 By Nasdaq GlobeNewswire

AnaptysBio and GSK-partnered immuno-oncology agents JEMPERLI (dostarlimab-gxly) and cobolimab show positive progress in two separate non-small cell lung cancer trials

05 Oct 2022 09:00:00 By Nasdaq GlobeNewswire

AnaptysBio Announces Sale of Zejula Royalties for Up To $45 Million

12 Sep 2022 07:30:00 By Nasdaq GlobeNewswire

AnaptysBio Reports HARP Phase 2 Top-Line Data of Imsidolimab in Moderate-to-Severe Hidradenitis Suppurativa

31 Aug 2022 16:15:00 By Nasdaq GlobeNewswire

AnaptysBio Announces Second Quarter 2022 Financial Results and Provides Pipeline Update

08 Aug 2022 16:05:03 By Nasdaq GlobeNewswire

AnaptysBio to Participate at the 2022 Wedbush PacGrow Healthcare Virtual Conference

05 Aug 2022 16:00:00 By Nasdaq GlobeNewswire

AnaptysBio to Participate at the 2022 Jefferies Healthcare Conference

02 Jun 2022 16:05:01 By Nasdaq GlobeNewswire

AnaptysBio Announces First Quarter 2022 Financial Results and Provides Pipeline Update

04 May 2022 16:15:01 By Nasdaq GlobeNewswire

AnaptysBio Announces Positive ANB032 (anti-BTLA agonist) Top-Line Phase 1 Data and Provides Pipeline Updates

27 Apr 2022 16:15:00 By Nasdaq GlobeNewswire

AnaptysBio Appoints Daniel Faga As Interim Chief Executive Officer

21 Mar 2022 16:15:00 By Nasdaq GlobeNewswire

AnaptysBio Reports Imsidolimab ACORN Phase 2 Clinical Trial Data in Moderate-to-Severe Acne

14 Mar 2022 16:20:00 By Nasdaq GlobeNewswire

AnaptysBio Announces Fourth Quarter and Full Year 2021 Financial Results and Provides Pipeline Update

07 Mar 2022 08:50:00 By Nasdaq GlobeNewswire

AnaptysBio To Present at the 40th Annual J.P. Morgan Healthcare Conference

05 Jan 2022 16:05:00 By Nasdaq GlobeNewswire

AnaptysBio Announces Appointment of Daniel Faga to Board of Directors

29 Nov 2021 16:05:50 By Nasdaq GlobeNewswire

AnaptysBio To Present at the 2021 Jefferies London Healthcare Conference

15 Nov 2021 19:24:01 By Nasdaq GlobeNewswire

AnaptysBio Announces Positive Rosnilimab Healthy Volunteer Phase 1 Top-Line Data

15 Nov 2021 09:00:01 By Nasdaq GlobeNewswire